* Parkinson’s disease
** symptoms
*** classical clinical features
- tremor-resting
- rigidity
- akinesia/bradykinesia
- posture and gait
*** cardinal symptoms
- bradykinesia
- tremor
- rigidity
- postural instability
*** [#B] similarity to side effects of which medication class?
antipsychotics
** causes
*** genetics
- parkin
- α-synuclein
*** environment :l:
**** oxidative stress
- dopamine neurons are acutely sensitive to oxidative damage
- In Parkinson’s disease, iron content is increased in the substantia nigra, which promotes ROS formation from H2O2 in the oxidation (via MAO) of dopamine. The Fe pathway is in opposition to the reductive pathway via glutathione/glutathione peroxidase.
**** neuroleptic-induced Parkinsonism
- phenothiazines
- bytrophenones
- resperine
** therapeutics
*** psychosis in late stage Parkinsonism
- low dose antipsychotics
  - Clozapine 25 – 50 mg/day 
  - Quetiapine 25 – 100 mg/day 
  - Pimavanserin (Nuplazid) 34 mg/day
*** rating scales
Unified Parkinson’s Disease Rating Scale
*** non-pharmacologic
- deep brain stimulation (preferred)
- exercise and diet
- PT, OT, speech therapy
** drug classes :l:
*** dopaminergic agents :l:
**** L-DOPA
***** efficacy
- most effective drug for Parkinsonian symptoms
- Virtually all patients with confirmed PD experience clinically significant benefit.
***** therapeutics
***** [#B] dosing strategy
- always use with Carbidopa
  - Carbidopa ≥ 65 mg
  - L-DOPA is always dosed with carbidopa---or else L-DOPA gets broken down in the periphery and never crosses the blood-brain-barrier
- nausea and vomiting signals that L-DOPA is being broken down; increase Carbidopa dose
***** adverse drug reactions
- end of dose wearing off due to short half-life
- peak dose dyskinesia
- nausea and vomiting (>80% on initiation); DA triggers emetic centers in CNS
- dyskinesias and motor fluctuations
*** DA metabolism inhibitors :l:
**** decarboxylase inhibitors :l:
***** Carbidopa
**** MAO-B inhibitors :l:
***** Selegiline
****** mechanism of action
- irreversible MAO-B inhibitor
- dose-dependent selectivity
****** therapeutics
adjunctive therapy with L-DOPA
****** brand :l:
******* Eldepryl
metabolized by CYP enzymes to l-amphetamine and l-methamphetamine
******* Zelapar
ODT
- bypasses first-pass metabolism
- doesn’t metabolize to amphetamine or methamphetamine metabolites
- fewer side effects
***** Rasagiline
****** brand
Azilect
****** mechanism of action
selective irreversible MAO-B inhibitor; can be used as monotherapy
****** benefits
- Decreases “off” time for patients on stable doses of carbidopa/levodopa
- No amphetamine like metabolites, so improved tolerability
***** Salfinamide
****** brand
Xadago
****** contraindications
severe hepatic impairment
****** adverse drug reactions
- involuntary movements
- falls
- nausea
- insomnia
**** COMT inhibitors
***** drugs :l:
****** Entacapone
******* brand
Comtan
****** Tolcapone
******* brand
Tasmar
******* toxicity
hepatotoxicity
***** therapeutics
- not effective as monotherapy
- always use COMT inhibitors with L-DOPA-Carbidopa
***** adverse drug reactions
- urinary discoloration
- delayed onset diarrhea
***** [#B] first line
entacapone
***** mechanism of action
inhibits peripheral breakdown of L-DOPA
*** dopamine agonists
**** drug classes
***** ergot derivatives :l:
****** bromocriptine
******* brand
Parlodel
******* indications
- Parkinsonism
- neuroleptic malignant syndrome
- diabetes
******* adverse drug reactions
Erythromelalgia and Raynaud’s phenomena
****** cabergoline
****** pergolide
******* brand
Permax
***** non-ergot derivatives :l:
****** pramipexole
******* brand
Mirapex
****** ropinirole
******* brand
Requip
****** rotigotine
******* brand
Neupro
**** adverse drug reactions
- not as effective as L-DOPA
- Erythromelalgia and Raynaud’s phenomena
*** antimuscarinic / anticholinergic agents
**** agents :l:
***** benztropine
****** brand
Cogentin
***** trihexyphenidyl
****** brand
Artane
**** [#B] indications
tremors
**** therapeutics
- younger patients ≤ 65 with temors (but intact cognitive function)
- caution in patients with cognitive decline
- monotherapy or adjunct to address tremors
**** [#A] contraindications
acute delirium
*** amantadine
**** indications
- tremor
- rigidity
- bradykinesia
**** mechanism of action
- releases dopamine
- inhibits dopamine reuptake
- weak, non-competitive NMDA receptor antagonist
** structure → drug
*** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/c/cf/3%2C4-Dihydroxy-L-phenylalanin_%28Levodopa%29.svg/1200px-3%2C4-Dihydroxy-L-phenylalanin_%28Levodopa%29.svg.png"/>
levodopa
*** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/9/99/Tolcapone.svg/1200px-Tolcapone.svg.png"/>
tolcapone
*** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/c/ca/Amantadine.svg/1200px-Amantadine.svg.png"/>
amantadine
*** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/7/7c/Benzatropine.svg/1200px-Benzatropine.svg.png"/>
benztropine
* Alzheimer’s
** drug classes
*** cholinesterase inhibitors
**** drugs :l:
***** donepezil
****** mechanism of action
non-competitive inhibitor of AChE
****** brand
Aricept
***** rivastigmine
****** brand
Exelon
****** mechanism of action
non-competitive (pseudo-irreversible) inhibitor of AChE
***** galantamine
****** brand
Razadyne
****** mechanism of action
Competitive, reversible centrally-acting cholinesterase inhibitor AND nAChR agonist
***** tacrine
****** [#C] brand
Cognex
****** significance
removed from the market due to hepatotoxicity
*** NMDA antagonists :l:
**** memantine
***** mechanism of action
Memantine binds to the magnesium biding site, and functions as an effective receptor blocker under conditions of excessive stimulation
***** therapeutics
- moderate-to-severe dementia/Alzheimer’s
- in combination with donepezil or monotherapy 
*** combination therapy :l:
**** donepezil + memantine
***** brand
Namzaric
*** other treatment options (not recommended)
- estrogen
- anti-inflammatory agents
  - NSAIDs
  - steroids
- lipid lowering agents; statins
- dietary/food supplements
  - Ginkgo biloba
  - vitamin E
  - huperzine A
  - polyphenols
  - AC1202 (Axona ®)
** therapeutics
*** contraindications
**** [#B] drugs
- anticholinergics
*** treatment strategy
**** mild-moderate
cholinesterase inhibitors
**** severe
+ memantine
+ donepezil
*** evaluation test
MMSE
** pathophysiology
*** risk factors
- older age
** structure → drug
*** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/5/54/Tacrine2DACS.svg/1200px-Tacrine2DACS.svg.png"/>
tacrine
*** <img src="https://upload.wikimedia.org/wikipedia/commons/thumb/9/92/Rivastigmine_Structural_Formulae.png/1280px-Rivastigmine_Structural_Formulae.png"/>
rivastigmine
